Open AccessMiR‐96 and miR‐183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology
Author(s) -
Yamada Yasutoshi,
Enokida Hideki,
Kojima Satoko,
Kawakami Kazumori,
Chiyomaru Takeshi,
Tatarano Shuichi,
Yoshino Hirofumi,
Kawahara Kazuya,
Nishiyama Kenryu,
Seki Naohiko,
Nakagawa Masayuki
Publication year - 2011
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2010.01816.x
Subject(s) - urine cytology , urine , cytology , medicine , urinary system , stage (stratigraphy) , cystoscopy , pathological , urology , receiver operating characteristic , microrna , cohort , gastroenterology , carcinoma , oncology , pathology , biology , paleontology , biochemistry , gene
A new diagnostic marker for urothelial carcinoma (UC) is needed to avoid painful cystoscopy during the initial diagnosis and follow‐up period. However, the current urine markers are useless because of the low sensitivities and specificities for UC detection. MiR‐96 and miR‐183 were differentially upregulated microRNA in our previous microRNA screening for UC. The expression levels of miR‐96 and miR‐183 in the urine samples were significantly higher in 100 UC than in healthy controls (miR‐96, P = 0.0059; and miR‐183, P = 0.0044). The receiver‐operating characteristic curve analyses demonstrated that each microRNA had good sensitivity and specificity for distinguishing UC patients from non‐UC patients (miR‐96, 71.0% and 89.2%; and miR‐183, 74.0% and 77.3%). Our cohort included 78 UC patients who had undergone urinary cytology. MiR‐96 was positively detected in 27 of 44 patients who had had a “negative” urinary cytology diagnosis. We combined the miR‐96 detection data with the urinary cytology data, and diagnosed 61 of 78 cases as UC; sensitivity rose from 43.6% to 78.2%. We found significant stepwise increases in miR‐96 and miR‐183 expression with advancing tumor grade (miR‐96, P = 0.0057; and miR‐183, P = 0.0036) and pathological stage (miR‐96, P = 0.0332; and miR‐183, P = 0.0117). The expression levels of the microRNA were significantly lower in urine collected after surgery (miR‐96, P = 0.0241; and miR‐183, P = 0.0045). In conclusion, miR‐96 and miR‐183 in urine are promising tumor markers for UC. In particular, miR‐96 may be a good diagnostic marker in combination with urinary cytology. ( Cancer Sci 2011; 102: 522–529)